AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

RecruitingNAAges 18 Years - anyAllUNC Lineberger Comprehensive Cancer Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervention, overall and stratified by race, and to evaluate the feasibility and acceptability of the PRISM intervention in the MBC population. Black women with MBC have shorter survival from the time of metastatic diagnosis to death, compared to White women with clinically similar disease, and may have more rapid declines in quality of life over time. Adverse social determinants of health may play a role in these outcome disparities, due to both social barriers in accessing care, and through direct stress-mediated biological effects on the host and tumor microenvironment. Interventions to reduce stre

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Participants are willing and able to comply with study procedures based on the judgement of the investigator. * Male and female patients of age \>18 years. * Pathologic diagnosis of metastatic breast cancer within 182 days prior to enrollment date. * Able to answer surveys and participate in counseling sessions in English (the patient's first language is not required to be English). * Indicate intent to receive ongoing cancer care at the enrolling institution. Exclusion Criteria: Individuals meeting any of the following exclusion criteria will be excluded from study participation. * Patient unwilling or unable to complete surveys via one of the following methods: (a) paper survey completed in clinic or mailed directly to patient's home address, including a pre-addressed, pre-stamped return envelope in the mailed survey packet, or (b) electronic survey links sent via emails or text link on a mobile device, tablet, laptop, or desktop computer. * Patient unwilling or unable to provide verbal or signed consent to participate. * Participant cannot read English. * Patient has permanently discontinued cancer-directed therapy or does not intend to receive any cancer-directed therapy, is receiving home or residential hospice care, is hospitalized, or is described as likely to die within 90 days or actively dying in last provider documentation, at the time of enrollment.
๐Ÿ’Š

What it tests

  • Promoting Resilience in Women with Breast Cancer (PRISM)
๐Ÿ“

Where

2 sites
The University of Alabama
Birmingham, United States
University of North Carolina
Chapel Hill, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy